The c-Myc oncogene drives malignant progression and induces robust anabolic and proliferative programmes leading to intrinsic stress. The mechanisms enabling adaptation to MYC-induced stress are not fully understood. Here we reveal an essential role for activating transcription factor 4 (ATF4) in survival following MYC activation. MYC upregulates ATF4 by activating general control nonderepressible 2 (GCN2) kinase through uncharged transfer RNAs. Subsequently, ATF4 co-occupies promoter regions of over 30 MYC-target genes, primarily those regulating amino acid and protein synthesis, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), a negative regulator of translation. 4E-BP1 relieves MYC-induced proteotoxic stress and is essential to balance protein synthesis. 4E-BP1 activity is negatively regulated by mammalian target of rapamycin complex 1 (mTORC1)-dependent phosphorylation and inhibition of mTORC1 signalling rescues ATF4-deficient cells from MYC-induced endoplasmic reticulum stress. Acute deletion of ATF4 significantly delays MYC-driven tumour progression and increases survival in mouse models. Our results establish ATF4 as a cellular rheostat of MYC activity, which ensures that enhanced translation rates are compatible with survival and tumour progression.
C ells utilize distinct stress response pathways to overcome environmental and physiological stresses. The integrated stress response (ISR) pathway promotes cellular adaptation to various stresses such as viral infection, haeme deprivation, hypoxia, nutrient deprivation and acidosis 1 . The ISR kinases-doublestranded RNA-dependent protein kinase (PKR), PKR-like endoplasmic reticulum kinase (PERK), general control nonderepressible 2 (GCN2, encoded by Eif2ak4 in mice and EIF2AK4 in humans) and haeme-regulated eukaryotic initiation factor 2α (eIF2α) kinase (HRI)-sense distinct stresses and catalyse phosphorylation of the α-subunit of eIF2α. Phosphorylation of eIF2α at serine 51 attenuates general protein synthesis while enhancing the translation of select transcripts containing distinct regulatory sequences in their 5′-untranslated region 2, 3 , most notably that of activating transcription factor 4 (ATF4). Once translated, ATF4 drives the transcription of genes involved in antioxidant response, autophagy, amino acid biosynthesis and transport 4, 5 . The ability of cancer cells to adapt to cell-extrinsic and -intrinsic stresses is critical for maintaining viability and growth. The ISR is essential in adaptation to extrinsic stresses present in the tumour microenvironment, such as hypoxia and nutrient deprivation [6] [7] [8] [9] . Cancer cells also experience intrinsic stress due to activation of oncogenes that increase bioenergetic processes [10] [11] [12] . In this context, amplification of the MYC oncogene, a frequent event in multiple human malignancies 13 , causes intrinsic stress due to enhanced protein synthesis and rewiring of metabolic pathways to meet the demands of rapid cell growth and proliferation 14, 15 . MYC upregulates protein synthesis by transactivating components of the translation machinery including initiation factors, ribosomes and tRNAs 15 , and targeting the translation machinery has proven to be effective in MYC-driven cancers 16, 17 . However, protein synthesis rates need to be controlled to a critical level to sustain survival of cancer cells during tumour development. For example, increased protein synthesis has to be accompanied by a concomitant increase in the folding capacity and size of the endoplasmic reticulum (ER) to avoid proteotoxicity 18 . We previously demonstrated that a MYC-induced increase in translation rates activates the PERK arm of ISR, which is required to support MYC-induced transformation and survival 11 , primarily by activating cytoprotective autophagy and attenuating Ca 2+ release from the ER 11 . Although ATF4 has been implicated in supporting survival of cancer cells experiencing a deficit of oxygen and nutrients, its role in oncogene-induced stress is not well characterized.
Here we show that optimal ATF4 expression on MYC dysregulation requires both PERK and GCN2, the latter being activated by excess uncharged tRNAs produced by increased MYC activity. 
ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression
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Induced ATF4, cooperatively with MYC, co-regulates a number of gene products, including eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), to fine-tune messenger RNA translation induced by MYC. Ablation of ATF4 results in increased ER stress and cytotoxicity, which is attenuated by mammalian target of rapamycin complex 1 (mTORC1) inhibition or expression of a dominant-negative 4E-BP1. Our results demonstrate the critical role of ISR signalling-induced ATF4 in supporting cell adaptation and survival during MYC-dependent tumour growth and progression.
Results
ATF4 is induced by MYC and promotes survival.
We previously reported that activation of MYC leads to phosphorylation of PERK and eIF2α 11 . To test whether MYC activation also induces ATF4, we analysed ATF4 expression following MYC induction in DLD-1 human colon adenocarcinoma cells and mouse embryonic fibroblasts (MEFs) stably expressing a tamoxifen-inducible MYC chimaera, MycER (hereafter, MycER cells). Treatment with 4-hydroxy-tamoxifen (4-OHT) led to accumulation of nuclear MYC and expression of ATF4 in both cell lines ( Fig. 1a and Supplementary  Fig. 1a) . Similarly, in the human Burkitt's lymphoma cell line P493-6, in which expression of MYC is turned off by administration of tetracycline, suppression of MYC resulted in a concomitant decrease of ATF4. When MYC levels were restored, ATF4 protein levels also recovered (Fig. 1b) . These data indicate that elevated MYC induces ATF4 expression.
Notably, ablation of ATF4 in MEFs significantly enhanced MYC-induced cell death, highlighted by increased levels of apoptosis markers including cleaved (cl)-poly (ADP-ribose) polymerase (cl-PARP) and cl-caspase-3 ( Fig. 1c) and reduced clonogenic survival (Fig. 1d) . Similarly, knockdown of ATF4 in DLD-1 cells also markedly enhanced apoptosis following MYC activation (Fig. 1e) . Collectively, these results highlight a role for ATF4 in promoting survival of transformed cells on MYC activation.
PERK and GCN2 are required for optimal phosphorylation of eIF2α following MYC induction. Activation of MYC enhances protein synthesis, resulting in ER stress 11, 19 . Although PERK is primarily responsible for phosphorylating eIF2α during MYC activation, residual phosphorylation of eIF2α in PERK-knockout cells prompted us to investigate whether other ISR kinases phosphorylate eIF2α in the absence of PERK 11 . We focused on GCN2, a kinase that we and others have shown to be activated in multiple solid tumours 7, 20 . Of note, we observed robust phosphorylation of GCN2 following MYC activation (Fig. 2a,b) . Consistent with our ) for the indicated time with or without washing for the indicated time. c, Immunoblot analysis of whole-cell lysates from ATF4 +/+ and ATF4 −/− MEFs treated with 4-OHT for indicated times. d, Clonogenic survival assays were performed after activating MYC in MEFs. Representative plates from three biological replicates are shown. Colonies were counted, and the surviving fraction is shown normalized to no-treatment control. Data are represented as mean ± s.d.; two-tailed Student's t-test. e, DLD-1 MycER cells were transfected with non-targeting (siNT) siRNA or siRNA targeting ATF4 (siATF4). Cells were treated with 4-OHT and the indicated proteins were detected by immunoblotting. Blots are representative of three biological replicates that showed similar results. Unprocessed scans of blots are shown in Supplementary Fig. 7 .
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NATuRE CEll BiOlOGY previous report 11 , phosphorylation of eIF2α was reduced, but still present on PERK knockdown (Fig. 2b) ; further, eIF2α phosphorylation was markedly reduced in the absence of both kinases, indicating functional compensation between these kinases on MYC activation (Fig. 2b) .
Consistent with loss of ATF4, knockdown of both PERK and GCN2 enhanced apoptosis following MYC activation (Fig. 2b) . Decreased expression of either PERK or GCN2 also reduced ATF4 protein levels (Fig. 2b )-this effect was more prominent in GCN2-knockdown cells. Similarly, transformed GCN2-deficient MEFs failed to induce ATF4 following MYC activation (Fig. 2c) . Of note, we observed higher activation of PERK in the absence of ATF4, suggesting increased ER stress in these cells (Fig. 2c) . Because GCN2-deficient cells still displayed residual eIF2α phosphorylation, yet ATF4 protein was expressed at a low level compared with GCN2-proficient cells, we hypothesized that GCN2 may regulate ATF4 at the transcriptional level. Indeed, induction of MYC resulted in a significant upregulation of ATF4 mRNA only in GCN2-proficient cells, although another well-characterized MYC-target gene-ornithine decarboxylase (ODC1)-was activated independently of GCN2 ( Supplementary Fig. 1b) . These results indicate that GCN2 is required for efficient ATF4 protein expression and for ATF4 mRNA transcription in response to MYC activation.
MYC increases the ratio of uncharged tRNAs leading to activation of GCN2. Amino acid deficiency leads to accumulation of uncharged tRNAs, which in turn bind to GCN2, resulting in its autophosphorylation and activation 3 . Activated GCN2 subsequently phosphorylates eIF2α, resulting in transient inhibition of general protein synthesis in conditions of amino acid GCT/C/A/G (Ala)
** * * * * *** *** *** *** *** *** *** *** *** ** ** * * * * * ** 
GCN2
−/− and ATF4 −/− MycER MEFs after 16 h of MYC activation. d, DLD-1 MycER cells were pretreated with DMSO or 50 μM ML60218 (an inhibitor of RNA polymerase III) for 2 h before MYC activation. Indicated protein levels were measured by immunoblotting from cytoplasmic lysates. e, Microarray analysis of aminoacyl-tRNAs of DLD-1 MycER cells after MYC induction at indicated times. Four independent experiments; one-way analysis of variance; *P < 0.05, **P < 0.01 and ***P < 0.001. Exact P values are listed in the source data. (−) Leu denotes Leu-deprived cells and the marked tRNAs reading Leu codons are uncharged (n = 1). tRNA probes are depicted with their cognate codon and the corresponding amino acid. Two different probes recognizing two different tRNA Leu isodecoders that pair to the same TTA/G Leu codon but differ in their sequence outside the anticodon were used on the arrays. Brackets show decreased charging of tRNA . Therefore, we sought to determine the mechanism of robust phosphorylation of GCN2 following MYC activation in cells grown in complete medium (Fig. 2a) . MYC has been shown to robustly enhance transcription of tRNAs in RNA polymerase III-dependent manner 22 , suggesting that newly synthesized, uncharged tRNAs might activate GCN2. To test this, we pretreated cells with ML60218, a specific inhibitor of RNA polymerase III 23 , to suppress tRNA synthesis before MYC activation. ML60218 markedly reduced GCN2 phosphorylation, indicating that RNA polymerase III-mediated transcription of tRNAs is required for MYC activation of GCN2 (Fig. 2d) .
RNA polymerase III regulates the transcription of other small structured RNAs, including tRNAs 22 . To directly analyse the levels of aminoacyl tRNAs following MYC activation, we used tRNAtailored microarrays that distinguish charged from uncharged tRNAs 24 . We found a marked and time-dependent increase in the levels of multiple uncharged tRNAs following MYC activation (Fig. 2e) . There was also a pronounced increase in the overall abundance of tRNAs ( Supplementary Fig. 1c ). Principal component analysis (PCA) revealed that these changes were strongly associated with tRNAs charged with hydrophobic amino acids, particularly branched amino acids ( Supplementary Fig. 1d ). As expected, leucine deprivation led to increased uncharging of all leucine-tRNA isoacceptors, demonstrating the specificity of the assay (Fig. 2e) . Furthermore, inhibition of RNA polymerase III markedly increased the fraction of charged tRNAs ( Supplementary Fig. 1e ) by reducing the total amount of all tRNAs ( Supplementary Fig. 1f ). These data indicate that MYC-induced RNA polymerase III-dependent transcription of tRNAs leads to transient accumulation of uncharged tRNAs, thereby activating GCN2.
ATF4 and MYC have common overlapping DNA-binding sites.
Since ATF4 is critical for survival following MYC activation (Fig. 1c-e) , we performed chromatin immunoprecipitation with sequencing (ChIP-seq) in DLD-1 MycER cells with or without MYC activation to map genes bound by ATF4 on a genome-wide scale. We identified 330 unique ATF4-binding sites that had ATF4 ChIPseq signal significantly enriched (false discovery rate, FDR < 5%; at least fourfold enrichment) over IgG control (Fig. 3a) . Levels of approximately 50% of the binding sites (165 out of 330) were significantly increased following MYC activation for 8 h (Fig. 3a) . A search for de novo motifs revealed that about 90% of identified ATF4-binding sites contained a previously established mouse ATF4-binding motif 25 (GSE35681) (Fig. 3b) . From the 165 ATF4-binding sites, we identified 79 genes (with Entrez IDs) in which ATF4 bound within 5 kb of at least one gene transcription start site (TSS). Of this subset, 16 genes are previously well-characterized ATF4 targets 4, 25 ( Supplementary Fig. 2a) . Analysis of the 79-gene list for functional and pathway enrichment showed significant overrepresentation of 11 functional categories and 10 pathways (Supplementary Fig. 2b ). As expected, one of the pathways was the unfolded protein response pathway, confirming the well-characterized role of ATF4 in this pathway. Other key functional categories were amino acid transport and biosynthesis and tRNA synthetases, underscoring the important role of ATF4 in protein synthesis ( Supplementary Fig. 2b ). We then analysed the list of genes for enrichment of known transcriptional regulators to identify potential ATF4 co-regulators (Fig. 3c) . As expected, ATF4 itself was the top significant hit with 16 known targets and a z score indicating positive regulation (z = 3.88, based on the majority of targets being upregulated by ATF4). Intriguingly, the only other significant transcriptional co-regulator was MYC, with a z score of at least 1.5, higher than additional factors such as p53, SP1 and Pax3 that also showed significant enrichment of targets.
We then performed ChIP-seq for MYC to map its global binding following stimulation with 4-OHT in the same cells. This experiment identified 3,263 peaks at 8 h of MYC induction that were within 5 kb of a gene TSS, 33 of which overlapped with ATF4-binding sites (28% of all ATF4 peaks), a significant overlap (2.1 more than expected by chance, P = 2 × 10 −5 by hypergeometric test) suggesting that a similar mechanism regulates a substantial subset of genes via both MYC and ATF4 (Fig. 3d) . Moreover, the promoters of genes with functions in amino acid transport (SLC7A11, SLC38A1 and SLC43A1) and tRNA charging (IARS, MARS and NARS) were occupied by both ATF4 and MYC (Fig. 3e) . We validated the ChIP-seq results by ChIP with quantitative PCR (ChIP-qPCR) ( Supplementary  Fig. 2c) . A ChIP-seq profile at a representative MYC and ATF4 target locus, TBC1D16 (Fig. 3e) , shows overlapping binding of MYC and ATF4 (Fig. 3f) . The ChIP-seq result suggests that MYC and ATF4 share common target genes, most of which are involved in amino acid transport and tRNA charging.
ATF4 suppresses mTORC1-dependent signalling to prevent proteotoxicity following MYC activation. We then sought to determine the mechanism by which ATF4 exerts its pro-survival effects following MYC dysregulation. Knowing the role of ATF4 in amino acid metabolism, antioxidant response and fatty acid synthesis, we attempted to rescue ATF4-deficient cells by supplying metabolites in culture media under conditions of MYC activation 4, 5, 26 . ATF4-deficient MEFs require the presence of non-essential amino acids and antioxidants to grow 4 . Supplementation with additional antioxidants or long-chain fatty acids did not rescue ATF4-deficient cells ( Supplementary Fig. 3a,b) . Notably, supplementation with α-ketoglutarate (αKG), an intermediary of the tricarboxylic acid cycle, delayed apoptosis during earlier (16 h) but not later (24 h) time points of MYC activation in ATF4-deficient MEFs ( Supplementary  Fig. 3a ,c). These results suggest that MYC activation imposes metabolic stress that can be partially relieved by αKG. However, additional ATF4-dependent processes must be activated to maintain long-term cell viability.
One of the targets identified by ChIP-seq that bound both MYC and ATF4 was EIF4EBP1, which encodes 4E-BP1, a negative regulator of the major cap-binding protein eIF4E and a downstream substrate of mTORC1 (Figs. 3e and 4a). mTORC1 integrates oncogenic stimuli into protein synthesis and cell growth signalling 27 by promoting phosphorylation of p70S6 kinase and 4E-BP1 28 . Hyperphosphorylation of 4E-BP1 by mTORC1 leads to its dissociation from eIF4E, enhancing cap-dependent protein translation downstream of eIF4E 29 . We confirmed that both ATF4 and MYC bind to the 4E-BP1 intron (Fig. 4a) . Moreover, 4E-BP1 mRNA level was reduced in the absence of ATF4 in both DLD-1 cells and MEFs ( Supplementary Fig. 4a,b) . We also observed that MYC activation enhanced levels of both phosphorylated and total 4E-BP1 (Fig.  4b ,d,e and Supplementary Fig. 4c ), yet there was a marked reduction in 4E-BP1 accumulation in the absence of ATF4 (Fig. 4b,d ,e and Supplementary Fig. 4c ) indicating that ATF4 is required for MYC induction of 4E-BP1. Of note, loss of ATF4 resulted in upregulation of PERK phosphorylation (Fig. 4c) , indicating ER stress activation. These results strongly suggest that 4E-BP1, downstream of the MYC-ATF4 axis, acts as a rheostat to set a protein synthesis level compatible with MYC oncogenic activity. ATF4-deficient cells also exhibited sustained phosphorylation of p70S6 kinase ( Fig. 4b and Supplementary Fig. 4c ). We next examined whether mTORC1 suppression in ATF4-deficient cells had an effect on cell death during MYC activation. Indeed, inhibition of mTORC1 by rapamycin treatment led to a marked decrease in MYC-dependent apoptosis and enhanced clonogenic survival in ATF4-deficient cells ( Fig. 4d and Supplementary Fig. 4c,d ).
To further probe the link between ATF4 and mTORC1 effectors, we knocked down p70S6 kinase and eIF4E, two major translational regulators downstream of mTORC1 signalling in the absence of ATF4. Consistent with the results of rapamycin treatment, knockdown of p70S6 kinase reduced cell death due to ATF4 Articles NATuRE CEll BiOlOGY deficiency when MYC was activated (Fig. 4e) . Combined knockdown of p70S6 kinase and ATF4 resulted in feedback upregulation of 4E-BP1 and phosphorylated (p)-4E-BP1 levels (Fig. 4e) . Additionally, knockdown of both p70S6 kinase and eIF4E further reduced cell death in the absence of ATF4 (Fig. 4e ). This suggests that ATF4 is required for defences against proteotoxicity in the context of hyperactive MYC-mTORC1 signalling funnelled through p70S6 kinase and eIF4E. 
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In support of this idea, inhibiting protein synthesis with low doses of cycloheximide led to a similar reduction in cell death in ATF4-deficient cells (Fig. 4f) . However, we did not observe a general increase in rate of translation by 35 S-methionine and cysteine labelling in the absence of ATF4, suggesting that synthesis of specific proteins rather than global translation is deregulated in ATF4-deficient cells and contributes to ER proteotoxicity ( Supplementary  Fig. 4e ). Furthermore, treatment with the chemical chaperone 
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NATuRE CEll BiOlOGY 4-phenylbutyric acid, which can protect against proteotoxicity in other stress contexts 30 , also promoted survival of ATF4-deficient cells following MYC activation (Supplementary Fig. 4f ). Since 4E-BP1 levels were reduced in the absence of ATF4, we overexpressed a mutant version of 4E-BP1 that cannot be phosphorylated and inactivated by mTORC1 31 . Expression of the 4E-BP1 mutant led to decreased apoptosis in ATF4-knockdown cells (Fig. 4g) , which was further reduced when combined with knockdown of p70S6 kinase ( Supplementary Fig. 4g ). Collectively, these data indicate that inhibiting both branches of mTORC1 signalling in ATF4-deficient cells reduces the demand of specific protein synthesis and promotes adaptation to hyperactive MYC-induced gene expression, mitigating proteotoxicity.
Inhibition of both PERK and GCN2 promotes survival of MYCdriven lymphoma-bearing mice. To test the importance of the GCN2-eIF2α-ATF4 pathway in vivo, we used a well-characterized mouse model of MYC-driven lymphoma, Eµ-Myc 32 , which harbours Myc coupled to the IgH enhancer and succumbs to aggressive B-cell lymphoma between 6 and 15 weeks of age 32 .
Eif2ak4
−/− (hereafter, Gcn2 −/− ) mice are viable and fertile, unlike Atf4 −/− mice, which display several pathological abnormalities in utero or shortly after birth [33] [34] [35] . We generated Eµ-Myc/+;Gcn2
+/− and Eµ-Myc/+;Gcn2 −/− mice ( Supplementary Fig. 5a ). Surprisingly, loss of GCN2 did not affect tumour initiation or progression or impact overall mouse survival ( Supplementary Fig. 5b ). Assessment of ISR signalling in B cells from each genotype revealed robust PERK and eIF2α phosphorylation and ATF4 upregulation in B-cell lymphoma compared with normal B cells from littermate controls, suggesting that PERK is probably compensating for loss of GCN2 ( Supplementary Fig. 5c ).
To test this notion, we transplanted either Eµ-Myc/+;Gcn2
or Eµ-Myc/+;Gcn2 −/− lymphomas ( Supplementary Fig. 5d ) into C57BL/6J mice and targeted PERK by using a potent and specific PERK inhibitor, LY-4 36 . LY-4 treatment was well tolerated and did not affect body weight or pancreas weight 37 , but significantly reduced phosphorylation of PERK ( Supplementary Fig. 5e,f,h ). Inhibition of PERK in mice bearing Eµ-Myc/+;Gcn2 −/− lymphomas, but not those bearing Eµ-Myc/+;Gcn2 +/+ lymphomas, increased overall survival ( Supplementary Fig. 5g ). Consistent with our in vitro data, inhibition of both PERK and GCN2 significantly reduced phosphorylation of eIF2α in the lymphoma cells ( Supplementary Fig. 5h,i) . Unexpectedly, inhibition of PERK and GCN2 did not reduce ATF4 protein levels, suggesting an eIF2α-independent regulation of ATF4 in the Eµ-Myc lymphoma model (Supplementary Fig. 5h ). One possible explanation for the modest increase in survival of these mice is the decreased phosphorylation of eIF2α, which can exacerbate ER stress in tumour cells due to unregulated protein translation 38 . These results underscore a strict selective pressure for maintenance of robust ATF4 levels in MYC-driven tumours. Supplementary Fig. 6a,b) . Following lymphoma onset, lymphoma cells were purified and allografted by intravenous injection into C57BL/6 syngeneic mice. The recipient mice were treated either with vehicle or tamoxifen to excise Atf4 specifically in the lymphoma cells (Fig. 5b) . Remarkably, excision of Atf4 significantly extended lymphoma-free and overall survival (Fig. 5b,c) .
This effect was not due to tamoxifen treatment because mice with Eµ-Myc/+;Atf4 wt/wt ;Rosa26-CreER T2/+ lymphomas displayed no significant difference in lymphoma-free or overall survival ( Fig. 5c and Supplementary Fig. 6c ).
To further assess the requirement for ATF4 in lymphoma progression, we treated a separate cohort of mice as above after lymphoma developed. Treatment with tamoxifen resulted in efficient ablation of Atf4 mRNA (Supplementary Fig. 6d ) and protein as well as reduction in expression of Atf3, an ATF4-target gene (Fig. 5d) and resulted in reduced lymph node weight (Fig. 5e) . Consistent with our in vitro data ( Fig. 4b and Supplementary Fig. 4c ), 4E-BP1 levels were significantly reduced in lymphoma cells following ATF4 ablation (Fig. 5f) . However, ATF4 expression returned to levels comparable with those of vehicle-treated groups by the endpoint of the experiment, suggesting that lymphoma cells that escaped ATF4 excision eventually formed lymphomas (Supplementary Fig. 6e ).
Similar to the lymphoma model, knockdown of ATF4 in DLD-1 MycER cells expressing a doxycycline-inducible short hairpin RNA directed against ATF4 significantly delayed tumour growth (Fig. 5g) . Collectively, the in vivo data support our hypothesis that ATF4 is critical for tumour growth driven by hyperactive MYC and indicate that targeting ATF4 in the context of activated MYC elicits potent anti-tumour effects.
We next assessed the levels of ISR signalling in B cells isolated from wild-type, pre-lymphoma and lymphoma-bearing Eµ-Myc mice. We noted higher expression of ATF4 in lymphoma samples compared with wild-type and pre-lymphoma samples (Fig. 6a) . Interestingly, levels of p-eIF2α, p-4E-BP1, 4E-BP1 and p-p70S6 kinase were higher in both pre-lymphoma and lymphoma samples than in wild-type samples (Fig. 6a) . Human Burkitt's lymphoma cell lines also displayed robust increases in ISR signalling and 4E-BP1 levels (Fig. 6b) . Similar results were seen in human breast and colon cancer cell lines compared with a human immortalized breast epithelial cell line and normal human colonocytes, respectively (Fig. 6c,d) .
To investigate the relevance of our findings in human malignancy, we analysed the expression of 4E-BP1 and tested its correlation with ATF4 activity in different cohorts of cancer patients by mining The Cancer Genome Atlas (TCGA) database. Since ATF4 is primarily regulated at the translational level, we used a group of ten well-characterized ATF4 targets (including ASNS, MTHFD2 and CHOP (also known as DDIT3)) as a surrogate for ATF4 activation 4, 25 . We found that 4E-BP1 levels were positively correlated with ATF4-target genes in diffuse large B-cell lymphoma (DLBCL), colorectal cancer, breast cancer and sarcoma (Fig. 6e) . Notably, high expression of 4E-BP1 also correlated with poor prognosis in patients with DLBCL (Fig. 6f) . These data further support the notion that ATF4-dependent modulation of MYC-driven translational alterations may play a role in progression of MYC-driven lymphomas.
Discussion
MYC activation is invariably linked with enhanced protein synthesis, which is critical for enhanced proliferation and expression of the tumorigenic properties of MYC 40 . However, increased translation increases demands on the ER, the site of glycosylation and folding of client proteins 41 . While PERK-mediated phosphorylation of eIF2α can provide initial relief from increased translation rates 11 , this mechanism may be insufficient for long-term survival due to a negative-feedback loop that promotes dephosphorylation of eIF2α 42 . This work demonstrates that ATF4 is critical for MYC-dependent tumour progression not only by supporting protein synthesis via expression of amino acid transporters and tRNA synthetases but also by preventing 'runaway' mRNA translation and subsequent proteotoxicity via prolonged upregulation of 4E-BP1 levels (Fig. 6g) .
Since ablating ATF4 expression did not increase global translation levels following MYC dysregulation, it is likely that ATF4 negatively regulates the expression of a specific set of proteins that traffic 
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NATuRE CEll BiOlOGY 4E-BP1 has been shown to inhibit cap-dependent translation and to promote survival under conditions of nutrient and oxidative stress 43 . Interestingly, higher expression of 4E-BP1 has been noted in multiple cancers [44] [45] [46] , and this high expression is associated with poor prognosis [45] [46] [47] . While ATF4 has been shown to regulate 4E-BP1 in the context of extrinsic physiologic stresses 48, 49 , its role in regulating 4E-BP1 in the context of MYC-deregulated tumour progression was unknown. Higher expression of 4E-BP1 seems paradoxical, as a hyperactive form of 4E-BP1 blocks MYC-induced tumorigenesis 50 . Indeed, our findings provide a context for the upregulation of 4E-BP1 expression in tumours: tumours maintain high levels of 4E-BP1 whose activity can be readily modulated by rapid phosphorylation and dephosphorylation, depending on favourable or unfavourable growth and proliferation conditions.
Our study also highlights the importance of using combined inhibition of both PERK and GCN2 in MYC-driven cancers to avoid compensation of ISR kinases in regulating p-eIF2α levels. Indeed, pharmacologic targeting of eIF2α phosphorylation in patient-derived prostate-xenograft models is effective in initiating a cytotoxic response that inhibits tumour growth 38 . However, in the lymphoma model tested here, ATF4 levels remained high despite the near complete inhibition of upstream canonical pathways (potentially via translational regulation by mTOR) 51 , and acute ATF4 ablation significantly decreased tumour growth and prolonged survival. This strongly implies that for certain malignancies, it might be essential to directly inhibit ATF4 activity for optimal anti-tumour outcome. In sum, the ISR transcription factor ATF4 is necessary for supporting and censoring protein translation thus promoting progression of MYC-driven tumorigenesis.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of code and data availability and associated accession codes are available at https://doi.org/10.1038/ s41556-019-0347-9. and Gcn2-knockout SV40-immortalized MEFs were maintained in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, 1× non-essential amino acids (Invitrogen, 11140050) and 55 μM β-mercaptoethanol (Millipore, ES-007-E). DLD-1 cells and MEFs were infected with retroviruses expressing MycER. MycER expression was induced with 250 nM or 500 nM 4-OHT (Sigma, H7904) in MEFs or DLD-1 cells, respectively. All cells were determined to be free of mycoplasma and cultured in 5% CO 2 at 37 °C. Normal human colonocytes were purchased from Cell Applications (732Cn-10a). Normal primary B cells were purchased from the Human Immunology Core at University of Pennsylvania. RNA polymerase III inhibitor ML60218 (577784-91-9), cycloheximide (C7698) and rapamycin (R8781) were purchased from Sigma, 4-phenylbutyric acid (130380250) was purchased from Fisher Scientific. Short interfering RNA (siRNAs) against ATF4 (L-005125-00), PERK (L-004883-00), GCN2 (L-005314-00), p70S6 kinase (L-003616-00), eIF4E (L-003884-00) and non-targeting siRNA control (D-001810-10) were purchased from Dharmacon. LY-4 was provided by Eli Lilly.
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Plasmids and retroviruses. MycER plasmid was provided by A. ThomasTikhonenko (The Children's Hospital of Philadelphia). Retrovirus construct and packaging plasmids, pEco-clontech (for mouse cells), pAmpho-clontech (for human cells) and gag pol were co-transfected into 293T cells using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Retroviral supernatant was collected 48-72 h after transfection and supplied with 8 μg ml −1 polybrene (Sigma, 28728-55-4) to infect target cells. Lentiviral TRIPZinducible short hairpin RNA directed against ATF4 plasmid was purchased from Dharmacon (V3THS_132755). Lentivirus was made in 293T cells by cotransfecting lentiviral vector and packaging plasmids. Lentiviral supernatant was collected 48-72 h after transfection and used to infect target cells. The dominant-negative mutant of 4E-BP1 (DN-4E-BP1) cDNA has been previously described 52 . The DN-4E-BP1 cDNA was subcloned into pMSCV-hygro to generate a constitutive mammalian expression vector with an N-terminal Flag tag (4E-BP1 mutant) used in this study. Retrovirus was made as described earlier to transfect DLD-1 and MycER cells. Transduced cells were selected with 400 μg ml −1 hygromycin to make stable cell lines.
Immunoblotting and antibodies. Cells were collected in ice-cold PBS and nuclear and cytoplasmic fractions were isolated by BioVision Nuclear Cytoplasm fractionation kit according to the manufacturer's instructions (BioVision, K266). RIPA buffer supplied with protease inhibitors (Roche, 11836153001) and phosphatase inhibitors (Sigma, p5726 and p0044) was used for whole lysate isolation. Protein concentrations were determined by DC protein assay (BioRad). Equal amounts of protein were loaded and resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes. All antibodies were incubated overnight at 4 °C overnight in 5% TBS (20 mM Tris base and 150 mM NaCl), 0.1% Tween-20. Membranes were washed and incubated with secondary antibodies for 1 h. Membranes were exposed to autoradiography films after washing with TBS, 0.1% Tween-20. The following antibodies were used for detecting proteins: ATF4 (Santa Cruz, sc-200×, c-20), MYC (Santa Cruz, sc-764, N-262) and ATF3 (Santa Cruz, sc-188, C-19). Rabbit β-tubulin (2146), mouse cl-PARP (mouse specific, 9548, 7C9), rabbit cl-PARP (human specific, 9541), rabbit cl-caspase-3 (9661), rabbit GCN2 (3302), rabbit PERK (3192, C33E10), rabbit p-PERK T980 (3179,16F8), rabbit p-4E-BP1 T37/46 (2855, 236B4), rabbit 4E-BP1 (9452), rabbit eIF4e (9742), rabbit p-p70S6 kinase T389 (9205), rabbit p70S6 kinase (2708, 49D7), rabbit p-eIF2α S51 (3597, 119A11) and rabbit eIF2α (9722) antibodies were purchased from Cell Signaling Technology. Rabbit p-PERK T982 was provided by Eli Lilly. Rabbit p-GCN2 T899 antibody (ab 75836) was purchased from Abcam. Mouse β-actin antibody (A5441, AC-15) was purchased from Sigma. Mouse RNA polymerase II antibody (39097) was purchased from Active Motif. Horseradish peroxidaseconjugated secondary antibodies, goat anti mouse (31430) and goat anti rabbit (31460) were purchased from Thermo Scientific.
Clonogenic survival assay. Cells were grown in complete medium in 60 mm dishes or in six-well plates. The following day, cells were treated with 4-OHT. Medium was changed after 24 h. Colonies that formed after a week were fixed with a solution of 10% methanol and 10% acetic acid and then stained with 0.4% crystal violet in 20% ethanol.
35 S-methionine and cysteine labelling. Cells were plated in a six-well dish. The following day, the cells were treated with 4-OHT for indicated times and labelled with 50 μCi Met/Cys Express Mix (PerkinElmer, NEG772014MC) for 1 h in methionine-and-cysteine-free DMEM (Invitrogen, 21013024). Cells were washed with ice-cold PBS and cell lysates were collected for protein. Equal amounts of protein was loaded and resolved by SDS-PAGE and transferred on to polyvinylidene fluoride membranes. Membranes were exposed to autoradiography films. Incorporation of 35 S was quantified with Image J 1.51r software. β-actin was used as a loading control.
Magnetic isolation of mouse B cells. Spleens and lymph nodes were excised from euthanized mice and immediately passed through a 70 μm cell strainer. Normal splenic B cells and B cells in lymphomas were isolated using mouse B-cell isolation kit (Miltenyi Biotec, 130-090-862) according to the manufacturer's instructions.
qPCR. RNA was collected for real-time qPCR analysis using the RNeasy Mini Kit (Qiagen, 74104) according to the manufacturer's instructions. RNA was reverse transcribed using AMV reverse transcriptase (Promega, M5108) in the presence of RNase inhibitor (Promega, N2111). qPCR was performed with Power SYBR green PCR master mix (Applied Biosystems, 4367659). QuantStudio 6 Flex Real-Time PCR System (Applied Biosystems) was used for data analysis. Primers used for qPCR are listed in Supplementary Table 1 .
Apoptosis analysis. Apoptosis was detected using the annexin V apoptosis detection kit (Invitrogen, A23204) according to the manufacturer's instructions. In brief, cells were collected and 1 × 10 5 cells were resuspended in 100 μl annexin-binding buffer. Five microlitres of the annexin V conjugate was added to each 100 µl of cell suspension and incubated at room temperature for 15 min. An additional 400 µl of annexin-binding buffer was added to cells. Cells were immediately analysed on a BD FACS Canto flow cytometer.
tRNA charging microarray. About 8 × 10
6 DLD-1 MycER cells were treated with 500 nM 4-OHT for 2 h, 4 h or 8 h; ethanol was used as vehicle. To determine the fraction of charged tRNAs, total RNA was isolated in mild acidic conditions using acidic phenol (pH 4.5), whose low pH preserves the aminoacyl moiety. Each sample was split into two aliquots, one of which was oxidized with periodate, which oxidizes the free non-aminoacyl groups leaving the changed tRNAs intact. Following subsequent deacylation the amino acid-protected tRNAs hybridize to Cy3-labelled RNA-DNA stem-loop oligonucleotide. The second aliquot was deacylated in 100 mM Tris (pH 9.0) at 37 °C for 45 min and hybridized to Atto647-labelled RNA-DNA stem-loop oligonucleotide and designated as total tRNA. Both aliquots were loaded on tRNA microarrays with tRNA probes covering the full-length sequence of cytoplasmic tRNA species as described previously 53 . For tRNA abundance, total RNA was isolated with TriReagent (Sigma Aldrich), which in alkaline pH simultaneously deacylates all tRNAs. The tRNAs were subsequently labelled with by ligating Cy3-labelled RNA-DNA stem-loop oligonucleotide. The tRNAs isolated from the vehicle-treated sample were labelled with Att647-labelled RNA-DNA stem-loop oligonucleotide, loaded on all arrays and used for comparison with all other samples. The arrays were normalized to spike-in standards, which were present in equimolar rations in both Cy3-and Atto647-labelled aliquots. The array processing and quantification was performed with in-house Python and R scripts. The data were submitted to the Gene Expression Omnibus database and can be accessed using accession number GSE116812.
ChIP. ChIP was performed as previously described Library preparation, sequencing and analysis. ChIP DNA from two independent experiments was submitted to Wistar genomics core (Wistar Institute) for library production using NEBNext Ultra II DNA Library Prep Kit for Illumina (E7645S) and NEBNext Multiplex Oligos for Illumina (E7335S) according to the manufacturer's instructions. The library fragments were assessed on an Agilent Technologies 2100 Bioanalyzer and yielded 150-350 bp products. An Illumina NextSeq 500 instrument was used for sequencing. Select targets were validated by qPCR and primers used for qPCR are listed in Supplementary Table 1. CHIP-seq data was aligned using bowtie 55 against the hg38 version of the human genome and HOMER software 56 was used call significant peaks against IgG control or between corresponding replicate pairs of samples using the -style factor option and only uniquely aligned reads with duplicates were removed. Significant peaks that passed a FDR < 5% threshold that were at least fourfold over IgG control were used to identify unique binding sites. Only results that were significant in comparison for both replicates were considered. De novo motif analysis was performed using HOMER software among the list of sites with significant ATF4 binding in at least one condition (both replicates). Overlap of binding sites with genes was done using the Ensemble 84 transcriptome database. Genes with a binding site within 5 kb of a TSS were considered. Significance of overlap was tested with a hypergeometric test using 23,869 Ensemble genes with Entrez ID as a population size. Gene-set enrichment analysis was done using QIAGEN's Ingenuity Pathway Analysis software (www.qiagen.com/ingenuity) using 'canonical pathways' and 'upstream analysis' options. Pathways with at least two member genes that passed FDR < 20%, with enrichment at least fivefold over the threshold and upstream regulators (transcription factors only) that passed P < 0.05 and had at least five target genes were considered. Functional and pathway enrichment analysis was done use DAVID software 57 and FDR < 20% categories enriched at least fivefold were considered. The data were submitted to the Gene Expression Omnibus database and can be accessed using accession number GSE117240. For transplantable lymphoma experiments, mice harbouring lymphomas were euthanized according to IACUC guidelines. Lymph nodes were collected immediately on ice and minced and passed through 70 µm cell strainer in 50% Isclove's medium and 50% DMEM supplemented with 10% FBS, 1% penicillinstreptomycin and 4 mM glutamine. Dead cells were removed by spinning cells in Ficoll-Paque PLUS (GE healthcare, 17-1440-02) at 800g for 10 min. Lymphoma cells were washed in PBS and 2 × 10 6 cells were injected into nine-week-old male C57BL/6J mice. Mice were monitored for lymphoma development by palpation every other day.
For PERK inhibitor (LY-4) experiments, nine-week-old male mice were injected with 2 × 10 6 Eµ-Myc/+;Gcn2 +/+ or Eµ-Myc/+;Gcn2 −/− lymphoma cells. After 3 d, mice were randomized to receive vehicle (Captisol, CYDEX) or 100 mg kg −1 LY-4 twice a day by oral gavage 3 d after lymphoma injection for the duration of the experiment. Moribund mice were euthanized according to IACUC guidelines and lymph nodes and spleen were collected and assessed for protein levels by immunoblot.
For ATF4 excision experiments, 2 × 10 6 Eµ-Myc/+;Rosa26-CreER
T2/+
;Atf4 wt/wt or Eµ-Myc/+;Rosa26-CreER T2/+ ;Atf4 fl/fl lymphoma cells were injected via tail vein into nine-week-old male C57BL/6J mice. Three days after lymphoma injection, mice were randomized to receive vehicle (peanut oil, Sigma) or 4 mg per 20 g tamoxifen (Sigma, T5648) by oral gavage for five consecutive days. Mice were monitored every other day for lymphoma development by palpation.
Three million DLD-1 MycER ishATF4 cells were injected in the flanks of 11-week-old male nude mice and MYC was activated by treating mice with 1 mg per mouse tamoxifen 3 d after tumour injection. Once tumours reached 100 cm 3 , mice were treated every other day with 2 mg per mouse doxycycline for the duration of the experiment. Tumour volume was measured every two to three days and calculated as V = (L × W × H)/2, where L is tumour length, W is tumour width and H is height.
Statistics and reproducibility. All cell culture experiments were performed three times unless otherwise noted in the legend. GraphPad Prism 7 and Excel 2010 were used for statistical analysis. Data are presented as mean ± s.d. or mean ± s.e.m. (as indicated in figure legends) and statistical significance was determined by unpaired, two-tailed Student's t-test. One-way analysis of variance was used to determine statistical differences in the tRNA microarray data. A P value less than 0.05 was considered statistically significant. For mouse survival analysis, KaplanMeier curves and log-rank tests were generated in GraphPad Prism 7 software. For xenograft experiment, two-way analysis of variance was used.
Patient data analysis. The gene expression using RNA-seq and survival information of the DLBCL dataset 58 were obtained from The National Cancer Institute Center for Cancer Genomics website, and gene expression information of three TCGA datasets was from University of California Santa Cruz Xena 59 . For each dataset, the normalized gene expression of EIF4EBP1 and another ten ATF4-targeted genes (DDIT3, ATF3, ASNS, SLC43A1, SLC1A5, GARS, NARS, MARS, PSAT1 and MTHFD2) were standardized to Z score, then the Pearson correlation between EIF4EBP1 and average ATF4-target genes was estimated. The visualization of linear relationships in Fig. 6e was performed using seaborn software version 0.9.0 (https://zenodo.org/record/883859#.Ww2av0gvzAQ). In addition, patients in DLBCL dataset were divided into two groups according to ATF4/EIF4EBP1 gene expression: low ATF4/EIF4EBP1 expression (≤median) and high ATF4/EIF4EBP1 expression (>median). Survival analysis using Kaplan-Meier and log-rank test between high and low ATF4/EIF4EBP1 expression groups were performed using lifelines software version 0.14.0 (https://zenodo.org/record/1252342#. Ww2WRUgvzAQ) as shown in Fig. 6f Last updated by author(s): May 21, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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